Go Deep
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 23,251 | 38.4 | 3.38 | 0.06 | 731.45 |
Akums Drugs and Pharmaceuticals Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 11,666,290,000.0 | 11,578,680,000.0 | 11,595,870,000.0 | 10,175,300,000.0 |
| Net Profit | 1,000,100,000.0 | 846,130,000.0 | 663,170,000.0 | 407,830,000.0 |
| EPS | 6.5 | 5.5 | 4.3 | 2.7 |
Akums Drugs and Pharmaceuticals Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 42,513,080,000.0 | 40,710,930,000.0 | 40,196,820,000.0 | 34,747,640,000.0 | — |
| Net Profit | 2,551,880,000.0 | 3,381,760,000.0 | -40,350,000.0 | 948,550,000.0 | — |
| EPS | 16.7 | 22.6 | -0.3 | 6.0 | — |
Akums Drugs and Pharmaceuticals Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 54,469,650,000.0 | 41,134,420,000.0 | 35,163,650,000.0 | 32,665,270,000.0 | — |
| Total Liabilities | 21,158,440,000.0 | 10,498,310,000.0 | 27,958,790,000.0 | 25,431,530,000.0 | — |
| Total Equity | 33,133,480,000.0 | 30,470,140,000.0 | 7,094,980,000.0 | 7,171,890,000.0 | — |
Owes vs Owns
Akums Drugs and Pharmaceuticals Limited owed ₹0.39 for every ₹1 it owned in Mar 2026, down from ₹0.78 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.39× | 0.26× | 0.80× | 0.78× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Akums Drugs and Pharmaceuticals Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 30.9%Receivables 14.6%Inventory 13.9%Fixed assets (tangible) 30.3%Other assets 10.2%
How it's funded — Mar 2026
Short-term debt 2.0%Long-term debt 1.4%Payables 11.1%Other liabilities 24.4%Shareholders' equity 61.2%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 1,680.9 | 581.9 | 287.8 | 150.5 |
| Receivables | 796.6 | 770.3 | 833.8 | 845.1 |
| Inventory | 755.7 | 680.9 | 630.4 | 729.8 |
| Fixed assets (tangible) | 1,649.5 | 1,563.6 | 1,390.7 | 1,212.3 |
| Intangible assets | 8.3 | 10.4 | 8.9 | 8.0 |
| Long-term investments | 0.2 | 0.3 | 0.0 | 0.0 |
| Other assets | 555.8 | 506.0 | 364.7 | 320.9 |
| Liabilities & equity | ||||
| Short-term debt | 107.3 | 13.7 | 413.3 | 421.5 |
| Long-term debt | 76.8 | 0.0 | 78.3 | 115.5 |
| Payables | 602.2 | 642.8 | 532.1 | 567.1 |
| Other liabilities | 1,329.6 | 393.4 | 1,772.2 | 1,439.0 |
| Shareholders' equity | 3,331.1 | 3,063.6 | 720.5 | 723.4 |
| Net tangible assets | 3,305.1 | 3,036.6 | 700.5 | 709.2 |
Akums Drugs and Pharmaceuticals Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 11,812,020,000.0 | 4,651,960,000.0 | 4,982,590,000.0 | 1,766,310,000.0 | — |
| Investing Activities | -9,302,680,000.0 | -5,478,430,000.0 | -3,304,150,000.0 | -3,047,020,000.0 | — |
| Financing Activities | 338,800,000.0 | 727,880,000.0 | -1,080,210,000.0 | 1,245,400,000.0 | — |